Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $35.37 down -4.22% from its previous closing price of $36.93. In other words, the price has decreased by -$4.22 from its previous closing price. On the day, 0.92 million shares were traded. VRNA stock price reached its highest trading level at $37.07 during the session, while it also had its lowest trading level at $34.95.
Ratios:
For a deeper understanding of Verona Pharma Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.03 and its Current Ratio is at 13.03. In the meantime, Its Debt-to-Equity ratio is 1.72 whereas as Long-Term Debt/Eq ratio is at 1.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $50.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 11 ’24 when ZACCARDELLI DAVID sold 2,400 shares for $5.00 per share. The transaction valued at 12,000 led to the insider holds 15,202,352 shares of the business.
Hahn Mark W sold 2,400 shares of VRNA for $12,000 on Nov 11 ’24. The Chief Financial Officer now owns 14,291,336 shares after completing the transaction at $5.00 per share. On Nov 11 ’24, another insider, MARK HAHN , who serves as the Officer of the company, bought 125,000 shares for $38.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 3022844160 and an Enterprise Value of 22941218816. For the stock, the TTM Price-to-Sale (P/S) ratio is 509.56 while its Price-to-Book (P/B) ratio in mrq is 22.18. Its current Enterprise Value per Revenue stands at 4079.164 whereas that against EBITDA is -152.639.
Stock Price History:
Over the past 52 weeks, VRNA has reached a high of $40.13, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is 8.54%, while the 200-Day Moving Average is calculated to be 64.48%.
Shares Statistics:
For the past three months, VRNA has traded an average of 1.04M shares per day and 1282690 over the past ten days. A total of 80.44M shares are outstanding, with a floating share count of 65.84M. Insiders hold about 19.54% of the company’s shares, while institutions hold 65.67% stake in the company. Shares short for VRNA as of 1730332800 were 7522563 with a Short Ratio of 7.26, compared to 1727654400 on 8011882. Therefore, it implies a Short% of Shares Outstanding of 7522563 and a Short% of Float of 9.6.
